Skip to content

Beta Cell Regeneration

We have an ambitious goal—to restore the body’s ability to create insulin-producing beta cells in people with type 1 diabetes (T1D). The JDRF Beta Cell Regeneration Program aims to both find and develop treatments that maintain the health and function of beta cells, and to discover and provide therapies to generate new beta cells.

Our Approach

In T1D, beta cells are stressed, hastening the autoimmune process that leads to their death. Beta cells, however, can persist long after T1D diagnosis, and in certain situations the body can even regrow new beta cells. This gives JDRF-funded researchers tools to develop therapies that relieve beta cell stress and promote their survival and regrowth.

  • Make beta cells multiply

    so people with T1D can live without lifelong external insulin

  • Promote the survival of beta cells

    so the “honeymoon period” (immediately following diagnosis when the pancreas is still producing insulin) can last years or even decades

  • Improve the function of remaining beta cells

    to reduce insulin dosage and improve outcomes

“The day I got discharged from the hospital, my pediatric endocrinologist gave us some great news; she had researched some options and there were clinical trials available to help extend the honeymoon phase. My participation in this trial was very beneficial for our whole family, giving us something positive and meaningful to focus on during the difficult period of adjusting to life with T1D.”

Abigail W.

15 years old, diagnosed at 13 years old

Abigail W..

Many Paths, One Purpose

Our research into beta cell regeneration technologies is just one potential pathway to finding a cure for T1D. Explore JDRF’s ambitious research portfolio.

All Research

Looking Ahead

To date, more than $190 million has been invested by JDRF in beta cell regeneration research. One day, T1D will become a reversible illness, without the threat of long- and short-term complications.